Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases.
Fontana D, Bertetto O, Fasolis G, Berruti A, Tarabuzzi R, Pagani G, Buniva T, Zolfanelli R, Pallotti S, Frezzotti L, Bumma C, Rossetti SR, Dogliotti L. Fontana D, et al. Among authors: dogliotti l. Tumori. 1998 Jan-Feb;84(1):39-44. doi: 10.1177/030089169808400108. Tumori. 1998. PMID: 9619712 Clinical Trial.
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, Gorzegno G, Fasolis G, Tampellini M, Porpiglia F, De Stefanis M, Fontana D, Bertetto O, Dogliotti L; Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese. Berruti A, et al. Among authors: dogliotti l. Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003. Urol Oncol. 2005. PMID: 15885575 Clinical Trial.
Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
Berruti A, Cerutti S, Fasolis G, Sperone P, Tarabuzzi R, Bertetto O, Pagani G, Zolfanelli R, Pallotti S, Bumma C, Fontana D, Rosseti SR, Dogliotti L, Angeli A. Berruti A, et al. Among authors: dogliotti l. Anticancer Res. 1997 Nov-Dec;17(6D):4697-702. Anticancer Res. 1997. PMID: 9494591 Clinical Trial.
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese. Berruti A, et al. Among authors: dogliotti l. J Urol. 2002 Jun;167(6):2361-7; discussion 2367. J Urol. 2002. PMID: 11992038
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.
Berruti A, Zola P, Buniva T, Baù MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D, Dogliotti L. Berruti A, et al. Among authors: dogliotti l. Anticancer Res. 1997 Jul-Aug;17(4A):2763-8. Anticancer Res. 1997. PMID: 9252712 Clinical Trial.
234 results